NCT07278089 AF Screening in Patients With Abnormal Echocardiographic Parameters
| NCT ID | NCT07278089 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tze-Fan Chao |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-03-17 |
| Primary Completion | 2031-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,000 participants in total. It began in 2025-03-17 with a primary completion date of 2031-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.
Eligibility Criteria
Inclusion Criteria: patients who met any of the following criteria 1. LAE: defined as LAD ≥ 45 mm or LAVI \> 34 ml/m2; 2. LVH: defined as LV septal or posterior wall thickness ≥ 15 mm; 3. E/e' \> 14; 4. grade II or III diastolic dysfunction; 5. VHD; 6. HF: defined as LVEF \< 40% or LVEF ≥40% with clinical presentation compatible with Framingham criteria, New York Heart Association functional classification II-IV, and N-terminal pro-B type natriuretic peptide (NT-proBNP) \> 125 pg/ml. Exclusion Criteria: * Patients with a history of AF or atrial flutter, congenital heart disease, acute coronary syndrome undergoing urgent percutaneous coronary intervention within 3 months, uncontrolled hyperthyroidism, end-stage renal disease, unstable hemodynamic status or any known major comorbidities or medical conditions with expected life expectancy less than 1 year are excluded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07278089 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07278089 currently recruiting?
Yes, NCT07278089 is actively recruiting participants. Contact the research team at eyckeyck@gmail.com for enrollment information.
Where is the NCT07278089 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07278089 clinical trial?
NCT07278089 is sponsored by Tze-Fan Chao. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.